These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32671595)

  • 21. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.
    Mahajan K; Nagendra L; Dhall A; Dutta D
    Eur J Intern Med; 2024 Jun; 124():99-107. PubMed ID: 38336550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials.
    Wu H; Shang H; Wu J
    Endocrine; 2018 May; 60(2):229-239. PubMed ID: 29397561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Lin YC; Lai TS; Wu HY; Chou YH; Chiang WC; Lin SL; Chen YM; Chu TS; Tu YK
    Clin Pharmacol Ther; 2020 Oct; 108(4):833-843. PubMed ID: 32320058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses.
    Shaya FT; Sing K; Milam R; Husain F; Del Aguila MA; Patel MY
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):239-248. PubMed ID: 31724105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of combination therapy with statins and ezetimibe on proinflammatory cytokines: A systematic review and meta-analysis of randomized controlled trials.
    Mostafa Arabi S; Sadat Bahrami L; MalekAhmadi M; Chambari M; Milkarizi N; Orekhov AN; Sahebkar A
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109477. PubMed ID: 36417822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
    Sakuma M; Toyoda S; Hashimoto R; Yazawa H; Masuyama T; Hirose S; Waku R; Hasumi H; Numao T; Abe S; Inoue T
    Hypertens Res; 2019 Dec; 42(12):1923-1931. PubMed ID: 31409915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
    Cha JJ; Hong SJ; Kim JH; Lim S; Joo HJ; Park JH; Yu CW; Lee PH; Lee SW; Lee CW; Moon JY; Lee JY; Kim JS; Park JS; Lee K; Lim SY; Na JO; Cho JM; Kim SY; Lim DS
    Am Heart J; 2023 Jul; 261():45-50. PubMed ID: 36934981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis.
    Zhu Y; Hu H; Yang J; Yao Q; Xu H; Yu Y; Liu T; Lin S
    Bosn J Basic Med Sci; 2020 May; 20(2):169-182. PubMed ID: 31668143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
    Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
    Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
    Robinson JG; Jayanna MB; Bairey Merz CN; Stone NJ
    PLoS One; 2020; 15(10):e0240166. PubMed ID: 33119602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.
    Guyton JR; Betteridge DJ; Farnier M; Leiter LA; Lin J; Shah A; Johnson-Levonas AO; Brudi P
    Diab Vasc Dis Res; 2011 Apr; 8(2):160-72. PubMed ID: 21562068
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.